@scientiarum.bsky.social
Excited to share our Nature Reviews Urology article highlighting the rapidly advancing field of PSMA-targeted therapies. Grateful to have contributed to this comprehensive review, and special thanks to Sola Adeleke for leading the effort.
🔗 www.nature.com/articles/s41...
🔗 www.nature.com/articles/s41...
Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer - Nature Reviews Urology
In this Perspective, the authors evaluate the current status of prostate-specific membrane antigen (PSMA) ligand-enabled imaging, summarizing novel developments, therapeutic advances and combinatorial...
www.nature.com
November 10, 2025 at 11:38 PM
Excited to share our Nature Reviews Urology article highlighting the rapidly advancing field of PSMA-targeted therapies. Grateful to have contributed to this comprehensive review, and special thanks to Sola Adeleke for leading the effort.
🔗 www.nature.com/articles/s41...
🔗 www.nature.com/articles/s41...
For those that missed the front row lecture last week, it's now available online: frontrow.scripps.edu/lectures/tra...
Reprogramming the immune system: A new era of precision immunotherapy for cancer and autoimmune disease - Travis Young, PhD - Scripps Research
Your immune system is your body’s natural defense, capable of identifying what belongs and what doesn’t. But when it falters, it can let cancer grow unchecked or mistakenly attack your own healthy tis...
frontrow.scripps.edu
August 25, 2025 at 6:22 PM
For those that missed the front row lecture last week, it's now available online: frontrow.scripps.edu/lectures/tra...
Thrilled to announce that our IND for CLBR001 + SWI019 has been cleared by FDA to test in patients with autoimmune conditions such as rheumatoid arthritis (RA), lupus, and systemic sclerosis. Find more information by visiting calibr.scripps.edu or clinicaltrials.gov (NCT06913608).
lnkd.in/eeXUuudj
lnkd.in/eeXUuudj
Calibr-Skaggs at Scripps Research - A Nonprofit Drug Discovery Hub
Calibr is a pioneering translational research institute dedicated to accelerating the next generation of medicines for critical unmet needs.
calibr.scripps.edu
April 18, 2025 at 11:20 PM
Thrilled to announce that our IND for CLBR001 + SWI019 has been cleared by FDA to test in patients with autoimmune conditions such as rheumatoid arthritis (RA), lupus, and systemic sclerosis. Find more information by visiting calibr.scripps.edu or clinicaltrials.gov (NCT06913608).
lnkd.in/eeXUuudj
lnkd.in/eeXUuudj
Reposted
Last week, the FDA cleared an IND for a chemo-free CAR-T cell therapy in autoimmune disease. Developed at Calibr-Skaggs, the drug discovery division of Scripps Research, CLBR001 + SWI019 now heads to trial for lupus, RA, systemic sclerosis & myositis. ow.ly/ZAcq50Vz8b5
FDA clears IND for clinical trial testing switchable CAR-T therapy in patients with autoimmune diseases, without chemotherapy
ow.ly
April 13, 2025 at 6:14 PM
Last week, the FDA cleared an IND for a chemo-free CAR-T cell therapy in autoimmune disease. Developed at Calibr-Skaggs, the drug discovery division of Scripps Research, CLBR001 + SWI019 now heads to trial for lupus, RA, systemic sclerosis & myositis. ow.ly/ZAcq50Vz8b5
Reposted
Amid the Trump admin's dismantling of the US scientific ecosystem, Nobel Prize-winner @ardemp.bskyverified.social writes on @cnn.com: "I’ve already been approached with an offer to relocate my lab to China, complete with a promise of 20 years of stable research funding." www.cnn.com/2025/04/09/h...
Nobel laureate: I owe America my success. Today, its scientific future is in danger | CNN
Dr. Ardem Patapoutian says he watches “with deep sadness as the United States’ remarkable scientific enterprise, which took generations of hard work and national investment to build, faces a concerted...
www.cnn.com
April 9, 2025 at 7:56 PM
Amid the Trump admin's dismantling of the US scientific ecosystem, Nobel Prize-winner @ardemp.bskyverified.social writes on @cnn.com: "I’ve already been approached with an offer to relocate my lab to China, complete with a promise of 20 years of stable research funding." www.cnn.com/2025/04/09/h...